326 related articles for article (PubMed ID: 25841057)
1. Cholesterol anchored arabinogalactan for asialoglycoprotein receptor targeting: synthesis, characterization, and proof of concept of hepatospecific delivery.
Pathak PO; Nagarsenker MS; Barhate CR; Padhye SG; Dhawan VV; Bhattacharyya D; Viswanathan CL; Steiniger F; Fahr A
Carbohydr Res; 2015 May; 408():33-43. PubMed ID: 25841057
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, characterization, and in vitro evaluation of palmitoylated arabinogalactan with potential for liver targeting.
Shah SM; Pathak PO; Jain AS; Barhate CR; Nagarsenker MS
Carbohydr Res; 2013 Feb; 367():41-7. PubMed ID: 23298829
[TBL] [Abstract][Full Text] [Related]
3. Design of cholesterol arabinogalactan anchored liposomes for asialoglycoprotein receptor mediated targeting to hepatocellular carcinoma: In silico modeling, in vitro and in vivo evaluation.
Pathak P; Dhawan V; Magarkar A; Danne R; Govindarajan S; Ghosh S; Steiniger F; Chaudhari P; Gopal V; Bunker A; Róg T; Fahr A; Nagarsenker M
Int J Pharm; 2016 Jul; 509(1-2):149-158. PubMed ID: 27231122
[TBL] [Abstract][Full Text] [Related]
4. Effect of galactose density on asialoglycoprotein receptor-mediated uptake of galactosylated liposomes.
Managit C; Kawakami S; Yamashita F; Hashida M
J Pharm Sci; 2005 Oct; 94(10):2266-75. PubMed ID: 16136555
[TBL] [Abstract][Full Text] [Related]
5. Novel Galactosylated Poly(ethylene glycol)-Cholesterol for Liposomes as a Drug Carrier for Hepatocyte-Targeting.
Zhang H; Xiao Y; Cui S; Zhou Y; Zeng K; Yan M; Zhao C
J Nanosci Nanotechnol; 2015 Jun; 15(6):4058-69. PubMed ID: 26369013
[TBL] [Abstract][Full Text] [Related]
6. Liposomes for targeting hepatocellular carcinoma: use of conjugated arabinogalactan as targeting ligand.
Shah SM; Goel PN; Jain AS; Pathak PO; Padhye SG; Govindarajan S; Ghosh SS; Chaudhari PR; Gude RP; Gopal V; Nagarsenker MS
Int J Pharm; 2014 Dec; 477(1-2):128-39. PubMed ID: 25311181
[TBL] [Abstract][Full Text] [Related]
7. Asialoglycoprotein receptor-targeted liposomes loaded with a norcantharimide derivative for hepatocyte-selective targeting.
Liu X; Han M; Xu J; Geng S; Zhang Y; Ye X; Gou J; Yin T; He H; Tang X
Int J Pharm; 2017 Mar; 520(1-2):98-110. PubMed ID: 28167263
[TBL] [Abstract][Full Text] [Related]
8. Novel derivatives of arabinogalactan, pullulan & lactobionic acid for targeting asialoglycoprotein receptor: Biomolecular interaction, synthesis & evaluation.
Warrier DU; Dhanabalan AK; Krishnasamy G; Kolge H; Ghormade V; Gupta CR; Ambre PK; Shinde UA
Int J Biol Macromol; 2022 May; 207():683-699. PubMed ID: 35248606
[TBL] [Abstract][Full Text] [Related]
9. Glycyrrhetinic Acid Liposomes Containing Mannose-Diester Lauric Diacid-Cholesterol Conjugate Synthesized by Lipase-Catalytic Acylation for Liver-Specific Delivery.
Chen J; Chen Y; Cheng Y; Gao Y
Molecules; 2017 Sep; 22(10):. PubMed ID: 28946644
[TBL] [Abstract][Full Text] [Related]
10. [In vitro targeting effect of lactoferrin modified PEGylated liposomes for hepatoma cells].
Wei MY; Zou Q; Wu CB; Xu YH
Yao Xue Xue Bao; 2015 Oct; 50(10):1272-9. PubMed ID: 26837173
[TBL] [Abstract][Full Text] [Related]
11. In vivo gene delivery to the liver using novel galactosylated cationic liposomes.
Kawakami S; Fumoto S; Nishikawa M; Yamashita F; Hashida M
Pharm Res; 2000 Mar; 17(3):306-13. PubMed ID: 10801219
[TBL] [Abstract][Full Text] [Related]
12. Asialoglycoprotein receptor-mediated gene transfer using novel galactosylated cationic liposomes.
Kawakami S; Yamashita F; Nishikawa M; Takakura Y; Hashida M
Biochem Biophys Res Commun; 1998 Nov; 252(1):78-83. PubMed ID: 9813149
[TBL] [Abstract][Full Text] [Related]
13. Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.
Pranatharthiharan S; Patel MD; Malshe VC; Pujari V; Gorakshakar A; Madkaikar M; Ghosh K; Devarajan PV
Drug Deliv; 2017 Nov; 24(1):20-29. PubMed ID: 28155331
[TBL] [Abstract][Full Text] [Related]
14. Asialoglycoprotein receptor mediated hepatocyte targeting - strategies and applications.
D'Souza AA; Devarajan PV
J Control Release; 2015 Apr; 203():126-39. PubMed ID: 25701309
[TBL] [Abstract][Full Text] [Related]
15. Chitooligosaccharides Modified Reduction-Sensitive Liposomes: Enhanced Cytoplasmic Drug Delivery and Osteosarcomas-Tumor Inhibition in Animal Models.
Yin X; Chi Y; Guo C; Feng S; Liu J; Sun K; Wu Z
Pharm Res; 2017 Oct; 34(10):2172-2184. PubMed ID: 28726003
[TBL] [Abstract][Full Text] [Related]
16. Larch arabinogalactan for hepatic drug delivery: isolation and characterization of a 9 kDa arabinogalactan fragment.
Prescott JH; Enriquez P; Jung C; Menz E; Groman EV
Carbohydr Res; 1995 Nov; 278(1):113-28. PubMed ID: 8536264
[TBL] [Abstract][Full Text] [Related]
17. Preparation and properties evaluation of a novel pH-sensitive liposomes based on imidazole-modified cholesterol derivatives.
Ju L; Cailin F; Wenlan W; Pinghua Y; Jiayu G; Junbo L
Int J Pharm; 2017 Feb; 518(1-2):213-219. PubMed ID: 27889588
[TBL] [Abstract][Full Text] [Related]
18. Current data on ATP-containing liposomes and potential prospects to enhance cellular energy status for hepatic applications.
Korb V; Tep K; Escriou V; Richard C; Scherman D; Cynober L; Chaumeil J; Dumortier G
Crit Rev Ther Drug Carrier Syst; 2008; 25(4):305-45. PubMed ID: 18540841
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of (Asp)7-CHOL-modified liposome prepared using pre-insertion and post-insertion methods for bone targeting in vivo.
Zhang L; Cao H; Zhang J; Yang C; Hu T; Li H; Yang W; He G; Song X; Tong A; Guo G; Li R; Jiang Y; Liu J; Cai L; Zheng Y
J Drug Target; 2017 Feb; 25(2):149-155. PubMed ID: 27416786
[TBL] [Abstract][Full Text] [Related]
20. Folate-PEG coated cationic modified chitosan--cholesterol liposomes for tumor-targeted drug delivery.
Wang H; Zhao P; Liang X; Gong X; Song T; Niu R; Chang J
Biomaterials; 2010 May; 31(14):4129-38. PubMed ID: 20163853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
